Value of Peptide Receptor Scintigraphy Using <sup>123</sup>I-Vasoactive Intestinal Peptide and <sup>111</sup>In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998

Raderer, Markus; Kurtaran, Amir; Leimer, M.; Angelberger, P.; Niederle, Bruno; Vierhapper, H.; Vorbeck, Friedrich; Hejna, Michael; Scheithauer, Werner; Pidlich, Johann; Virgolini, Irene

doi:10.1200/jco.2000.18.6.1331

Cited by 62 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current gold standard for functional imaging of neuroendocrine tumors is somatostatin receptor scintigraphy (SRS) with 111 In-diethylenetriaminepentaacetic acidoctreotide (4,5), targeting the somatostatin receptors with the highest affinity for subtype 2. The increased monoamine metabolism also observed in neuroendocrine tumors can be visualized by the 123 I-labeled noradrenalin analog metaiodobenzylguanidine (MIBG).…”

mentioning

confidence: 99%

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Binderup¹,

Knigge²,

Loft³

et al. 2010

J Nucl Med

258

166

View full text Add to dashboard Cite

Functional techniques are playing a pivotal role in the imaging of cancer today. Our aim was to compare, on a head-to-head basis, 3 functional imaging techniques in patients with histologically verified neuroendocrine tumors: somatostatin receptor scintigraphy (SRS) with 111 In-diethylenetriaminepentaacetic acidoctreotide, scintigraphy with 123 I-metaiodobenzylguanidine (MIBG), and 18 F-FDG PET. Methods: Ninety-six prospectively enrolled patients with neuroendocrine tumors underwent SRS, 123 I-MIBG scintigraphy, and 18 F-FDG PET on average within 40 d. The functional images were fused with low-dose CT scans for anatomic localization, and the imaging results were compared with the proliferation index as determined by Ki67. Results: The overall sensitivity of SRS, 123 I-MIBG scintigraphy, and 18 F-FDG PET was 89%, 52%, and 58%, respectively. Of the 11 SRS-negative patients, 7 were 18 F-FDG PET-positive, of which 3 were also 123 I-MIBG scintigraphypositive, giving a combined overall sensitivity of 96%. SRS also exceeded 123 I-MIBG scintigraphy and 18 F-FDG PET based on the number of lesions detected (393, 185, and 225, respectively) and tumor subtypes. 123 I-MIBG scintigraphy was superior to 18 F-FDG PET for ileal neuroendocrine tumors, and 18 F-FDG PET was superior to 123 I-MIBG scintigraphy for pancreaticoduodenal neuroendocrine tumors. The sensitivity of 18 F-FDG PET (92%) exceeded that of both SRS (69%) and 123 I-MIBG scintigraphy (46%) for tumors with a proliferation index above 15%. Conclusion: The overall sensitivity of 123 I-MIBG scintigraphy and 18 F-FDG PET was low compared with SRS. However, for tumors with a high proliferation rate, 18 F-FDG PET had the highest sensitivity. The results indicate that, although SRS should still be the routine method, 18 F-FDG PET provides complementary diagnostic information and is of value for neuroendocrine tumor patients with negative SRS findings or a high proliferation index.

show abstract

mentioning

confidence: 99%

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Binderup¹,

Knigge²,

Loft³

et al. 2010

J Nucl Med

258

166

View full text Add to dashboard Cite

show abstract

“…М. Raderer и соавт. продемонстрировали результаты ретроспективного анализа СРС с 111 In-DTPA-октреотидом у 104 больных, согласно кото-рому чувствительность данного метода со-ставила >80% среди первичных НЭО с мета-статическим поражением печени [57,58], что свидетельствует об информативности данного исследования для первичного ста-дирования опухоли и поиска рецидива. Применение гибридных методов визуализа-ции, таких как ОФЭКТ/КТ и ПЭТ/КТ, способ-ствовало улучшению результатов диаг-ностики НЭО.…”

Section: лучевая визуализацияunclassified

Radionuclide imaging and therapy in patients with neuroendocrine tumors

et al. 2018

View full text Add to dashboard Cite

Нейроэндокринные опухоли представляют собой гетерогенную группу опухолей, возникающих из энтерохром-аффинных клеток диффузной нейроэндокринной системы и встречающихся в 0,5% случаев всех новообразований. За последние годы отмечается значительный рост заболеваемости нейроэндокринными опухолями, что безуслов-но связано с усовершенствованием методов их диагностики. Однако, несмотря на значительные успехи в изучении биологических и молекулярных механизмов поведения данной группы заболеваний, формирование единого алго-ритма диагностики и лечения нейроэндокринных опухолей остается затруднительным и по сей день. Лечение нейроэндокринных опухолей во многом зависит от их функционального статуса и стадии заболевания. Наиболее предпочтительным подходом в лечении локализованных форм нейроэндокринных опухолей остается хирургиче-ский. В то же время для больных с распространенными процессами, характеризующимися наличием отдаленных метастазов, на сегодняшний день доступен широкий спектр терапевтических стратегий. Среди них можно выде-лить контроль над синдромами, ассоциированными с гиперсекрецией тех или иных гормонов, выполнение цито-редуктивных вмешательств, системную химиотерапию, применение аналогов соматостатина, а также радиотар-гетную терапию. Однако алгоритм выбора того или иного терапевтического подхода в современной клинической практике у разнородной группы больных с нейроэндокринными опухолями требует дальнейшего обсуждения. Ключевые слова: нейроэндокринные опухоли, радионуклидная диагностика, радиотаргетная терапия, аналоги соматостатина, октреотид, онкология, радиология.Neuroendocrine tumors (NETs) are heterogeneous group of the tumors that arise from the enterochromaffin cells of the diffuse neuroendocrine system and occurr in 0.5% of all neoplasms. Recently there has been a significant increase in the incidence of neuroendocrine tumors, which is undoubtedly associated with the improvement of diagnostic methods. However, despite significant success in studying the biological and molecular mechanisms of its behavior, a single algorithm for the diagnosis and treatment of neuroendocrine tumors remains unclear today. Treatment of neuroendocrine tumors largely depends on their functional status and the stage of the disease. While the treatment of localized NETs is surgical resection, varieties of therapeutic options are available for patients with advanced NETs. These include medical control of excess hormone levels and associated symptoms, cytoreductive surgery for patients with advanced disease, systemic chemotherapy, somatostatin analogues, and peptide receptor-targeted radionuclide therapy. However, the right choice of the therapeutic approach in current clinical practice in heterogeneous group of patients with neuroendocrine tumors requires further discussion.

show abstract

“…Due to the high densities of VPAC1 on some tumor cells (100,000/cell), radiolabeled VIP analogs have been used to image tumors. 123 I-VIP was used to image primary tumors in colon cancer and carcinoid patients [63,78]. Also, a 99m Tc-labeled VIP analog named TP-3645 was used to image tumors in breast cancer patients [59].…”

Section: Vasoactive Intestinal Peptidementioning

confidence: 99%

Neuropeptides as lung cancer growth factors

Moody¹,

Moreno²,

Jensen³

2015

Peptides

View full text Add to dashboard Cite

Value of Peptide Receptor Scintigraphy Using ¹²³I-Vasoactive Intestinal Peptide and ¹¹¹In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998

Cited by 62 publications

References 19 publications

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Radionuclide imaging and therapy in patients with neuroendocrine tumors

Neuropeptides as lung cancer growth factors

Contact Info

Product

Resources

About

Value of Peptide Receptor Scintigraphy Using 123I-Vasoactive Intestinal Peptide and 111In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998

Cited by 62 publications

References 19 publications

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Radionuclide imaging and therapy in patients with neuroendocrine tumors

Neuropeptides as lung cancer growth factors

Contact Info

Product

Resources

About

Value of Peptide Receptor Scintigraphy Using ¹²³I-Vasoactive Intestinal Peptide and ¹¹¹In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, ¹²³I-MIBG Scintigraphy, and ¹⁸F-FDG PET